Anti-VEGF Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Pipeline

Phase 2: 2

Top Sponsors

Shanghai Zhongshan Hospital1
Shandong Cancer Hospital and Institute1
BioAge Labs, Inc.1

Indications

Liver Disease2
Liver Cancer2
Hepatocellular Carcinoma2
Cancer2
Hepatic Artery Infusion Chemotherapy1

Other2 trials

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Phase 2

McAllen, Texas1 trial

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

Site 106

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.